Search research articles
Contact Us
Filters
Showing results (21-30 of 97) with videos related to
Page
of 10
Sort By:
Journal of Lipid Research
|
October 7, 2016
Effect of evolocumab on cholesterol synthesis and absorption
Matthew Peach, Ren Xu, Dan Fitzpatrick, et al.
Journal of the American Heart Association
|
March 23, 2019
Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy
Dick C Chan, Gerald F Watts, Blai Coll, et al.
Clinical Pharmacokinetics
|
January 22, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sreeneeranj Kasichayanula, Anita Grover, Maurice G Emery, et al.
JAMA Cardiology
|
January 26, 2017
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Nihar R Desai, Robert P Giugliano, Scott M Wasserman, et al.
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J Koren, Rob Scott, Jae B Kim, et al.
The Journal of Biological Chemistry
|
June 17, 2003
A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling
Ruey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Congestive Heart Failure (Greenwich, Conn.)
|
June 19, 2010
Treatment of anemia with darbepoetin alfa in heart failure
William T Abraham, Inder S Anand, Marc Klapholz, et al.
The Lancet. Diabetes & Endocrinology
|
February 13, 2016
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar, David Preiss, Jennifer G Robinson, et al.
European Heart Journal
|
March 23, 2018
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
JAMA
|
November 7, 2012
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
David Sullivan, Anders G Olsson, Rob Scott, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 97) with videos related to
Sort By:
Page
of 10
Journal of Lipid Research
|
October 7, 2016
Effect of evolocumab on cholesterol synthesis and absorption
Matthew Peach, Ren Xu, Dan Fitzpatrick, et al.
Journal of the American Heart Association
|
March 23, 2019
Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy
Dick C Chan, Gerald F Watts, Blai Coll, et al.
Clinical Pharmacokinetics
|
January 22, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sreeneeranj Kasichayanula, Anita Grover, Maurice G Emery, et al.
JAMA Cardiology
|
January 26, 2017
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Nihar R Desai, Robert P Giugliano, Scott M Wasserman, et al.
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J Koren, Rob Scott, Jae B Kim, et al.
The Journal of Biological Chemistry
|
June 17, 2003
A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling
Ruey-Bing Yang, Chi Kin Domingos Ng, Scott M Wasserman, et al.
Congestive Heart Failure (Greenwich, Conn.)
|
June 19, 2010
Treatment of anemia with darbepoetin alfa in heart failure
William T Abraham, Inder S Anand, Marc Klapholz, et al.
The Lancet. Diabetes & Endocrinology
|
February 13, 2016
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar, David Preiss, Jennifer G Robinson, et al.
European Heart Journal
|
March 23, 2018
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
JAMA
|
November 7, 2012
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
David Sullivan, Anders G Olsson, Rob Scott, et al.
Page
of 10